Juva Life Highlights First Quarter 2022 Financial Results Showing 97%

VANCOUVER, British Columbia, July 19, 2022 (GLOBE NEWSWIRE) — Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life”, “Juva” or the “Company”), a life sciences company with pharmaceutical research and development and consumer cannabis production and distribution, today reported financial and operating results for the first quarter of 2022.

$1.16 million in revenue was generated in the first quarter of 2022, nearly double the revenue of $0.58 million in the same period a year earlier. This growth was driven by increased sales in its retail business as well as bulk cannabis flower wholesale sales. Net loss for the quarter decreased from $5.5 million in Q1 2021 to $3 million in Q1 2022.

In Q1 2022, Juva advanced JUVA-019, a new proprietary compound that has already demonstrated potent anti-inflammatory properties in phenotypic inflammation assays from discovery through preclinical development. She also advanced JUVA-041, a second proprietary novel compound, into preclinical development, further strengthening the company’s discovery strategy and technology platform. Juva Life has filed patents on both compounds and plans to advance them to the standardized clinical stage in the coming months. Also on the clinical side of the company, Juva launched the Journal app which provides cannabis consumers with a daily tracking solution to monitor the impact of their cannabis use on their personal health and well-being, furthering the mission of Juva to prove the therapeutic value of cannabis.

Additionally, the company completed the final phase of construction of its 30,000 square foot Stockton cultivation facility, which more than doubled the facility’s growth capacity without adding additional costs and maximizing cultivation systems. of the installation.

“As we enter the second half of the year, we are extremely confident about our progress in our life science research and cannabis operations,” said Doug Chloupek, CEO and Founder of Juva. “Our research team is advancing at an unprecedented rate to prove the potential therapeutic value of our two lead candidates, JUVA-019 and JUVA-041. We have already seen extremely promising preclinical results in their ability to inhibit inflammation, and we are advancing them through their clinical pipeline as quickly as possible. On the cannabis operations side, our grow facility in Stockton is fully comprehensive and firing on every cylinder. The delivery business continues to grow and we are thrilled to have received one of the first and only retail licenses in Redwood City. Overall, the first quarter was a great first quarter for Juva, and we look forward to sharing our second quarter results soon.


-Doug Chloupek-

Doug Chloupek, CEO and Founder

Juva Life Inc.

[email protected]

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (ENG: 4VV)

Juva Life uses cutting-edge science to discover, develop and market safe and effective wellness and pharmaceutical products, both in the cannabis consumer segment and in the non-cannabinoid medical industry. The company is successfully executing on its 2018 roadmap, initially starting with the standardization of cultivation, extraction and formulation to deliver repeatable benefits to consumers. Juva is building on these skills in natural product process chemistry, to now include discovery pharmacology. The Company will leverage revenues from its retail operations to advance its clinical and consumer development efforts of Juva-019 and Juva-041, as well as other potentially valuable non-cannabinoid bioactives with important applications in consumer products and pharmaceuticals. Juva strives to challenge the cannabis market with the industry’s investment-grade, next-generation business model. Learn more about: https://juvalife.com/.

For more information, please contact:

Juva Life Investor Relations

Such : +1 833-333-5882 (JUVA)

E-mail: [email protected]

Investor Relations:
Kyle Porter
[email protected]

Corporate Contact:
1.833.333.JUVA (5882)

Forward-looking statement

This press release contains statements and information which, to the extent that they are not historical facts, may constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking information may include financial and other projections, as well as statements regarding future economic plans, objectives or performance, or assumptions underlying any of the foregoing. In some instances, forward-looking statements may be identified by words such as “may”, “would”, “could”, “will”, “likely”, “unless”, “anticipate”, “believe”, “have the ‘intention’, ‘plan’, ‘forecast’, ‘project’, ‘estimate’, ‘prospect’, or their negative form or other similar expressions relating to matters which are not historical facts. Examples of such statements include, but are not limited to, statements regarding the Company’s objectives and business plans; product development, marketing strategy and future collaborations.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the information. forward-looking, including, without limitation, risks related to the Company’s future business plans; the risks that the Company may not be able to retain its key personnel; the risks that the Company may not be able to obtain financing on reasonable terms or at all, as well as all other risks described in the Company’s management report for the financial year ended December 31, 2020 under the section “Risks and uncertainties”. Accordingly, readers should not place undue reliance on such forward-looking information. Further, any forward-looking information speaks only as of the date such statement is made. New factors appear from time to time and it is not possible for the management of the Company to foresee all of these factors and to assess in advance the impact of each of these factors on the activities of the Company or the the extent to which any factor, or combination of factors, could cause actual results to differ materially from those contained in the forward-looking information. The Company undertakes no obligation to update forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unforeseen events, except as required by law, including securities laws.

CSE does not accept responsibility for the adequacy or accuracy of this release.

Source link

Comments are closed.